{"title":"纵隔低温活检在HIV患者纵隔淋巴结病诊断中的价值。","authors":"Olivia Sánchez-Cabral, Iván Armando Osuna-Padilla, Adnan Majid, Belinda Maricela Contreras-Garza, María Fernanda Negrete-García","doi":"10.2147/HIV.S499971","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Mediastinal diseases in HIV patients show complex diagnostic challenges due to opportunistic infections and rare neoplasms. While Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a key technique, its effectiveness is limited as it only provides cytological samples. Endobronchial ultrasound-guided mediastinal cryobiopsy (CryoEBUS) emerges as a promising alternative, yielding larger and higher-quality samples. This study, the first in Mexico and the first worldwide in HIV patients, evaluates its diagnostic efficacy compared to EBUS-TBNA, highlighting its potential to improve disease management in immunocompromised populations.</p><p><strong>Materials and methods: </strong>A prospective cross-sectional study has been conducted from April 2023 to October 2023 at a tertiary center for respiratory diseases in Mexico, evaluating the usefulness of the endobronchial ultrasound-guided mediastinal cryobiopsy (CryoEBUS) diagnostic in HIV-positive patients with mediastinal lymphadenopathy ≥1cm. Patients underwent CryoEBUS, with outcomes assessed via pathology and microbiology reports.</p><p><strong>Results: </strong>Eleven patients were included (64% male, mean age 39.1 years). CryoEBUS yielded diagnostic results in 82% of cases compared to 72% for bronchoalveolar lavage (BAL) and 50% for EBUS alone. Combined CryoEBUS and BAL demonstrated the highest yield (91%).</p><p><strong>Conclusion: </strong>In patients with HIV and mediastinal lymphadenopathy, mediastinal cryobiopsy has proven to be a useful, effective technique with a high diagnostic yield, especially for benign pathologies. It has also proven to be a safe technique and when combined with other lung sampling techniques, it improves the diagnostic yield of infectious diseases and rare neoplasms.</p>","PeriodicalId":46555,"journal":{"name":"HIV AIDS-Research and Palliative Care","volume":"17 ","pages":"135-141"},"PeriodicalIF":1.5000,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12155373/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Usefulness of Mediastinal Cryobiopsy in the Diagnosis of Mediastinal Lymphadenopathy in HIV Patients.\",\"authors\":\"Olivia Sánchez-Cabral, Iván Armando Osuna-Padilla, Adnan Majid, Belinda Maricela Contreras-Garza, María Fernanda Negrete-García\",\"doi\":\"10.2147/HIV.S499971\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Mediastinal diseases in HIV patients show complex diagnostic challenges due to opportunistic infections and rare neoplasms. While Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a key technique, its effectiveness is limited as it only provides cytological samples. Endobronchial ultrasound-guided mediastinal cryobiopsy (CryoEBUS) emerges as a promising alternative, yielding larger and higher-quality samples. This study, the first in Mexico and the first worldwide in HIV patients, evaluates its diagnostic efficacy compared to EBUS-TBNA, highlighting its potential to improve disease management in immunocompromised populations.</p><p><strong>Materials and methods: </strong>A prospective cross-sectional study has been conducted from April 2023 to October 2023 at a tertiary center for respiratory diseases in Mexico, evaluating the usefulness of the endobronchial ultrasound-guided mediastinal cryobiopsy (CryoEBUS) diagnostic in HIV-positive patients with mediastinal lymphadenopathy ≥1cm. Patients underwent CryoEBUS, with outcomes assessed via pathology and microbiology reports.</p><p><strong>Results: </strong>Eleven patients were included (64% male, mean age 39.1 years). CryoEBUS yielded diagnostic results in 82% of cases compared to 72% for bronchoalveolar lavage (BAL) and 50% for EBUS alone. Combined CryoEBUS and BAL demonstrated the highest yield (91%).</p><p><strong>Conclusion: </strong>In patients with HIV and mediastinal lymphadenopathy, mediastinal cryobiopsy has proven to be a useful, effective technique with a high diagnostic yield, especially for benign pathologies. It has also proven to be a safe technique and when combined with other lung sampling techniques, it improves the diagnostic yield of infectious diseases and rare neoplasms.</p>\",\"PeriodicalId\":46555,\"journal\":{\"name\":\"HIV AIDS-Research and Palliative Care\",\"volume\":\"17 \",\"pages\":\"135-141\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-06-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12155373/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HIV AIDS-Research and Palliative Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/HIV.S499971\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV AIDS-Research and Palliative Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/HIV.S499971","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
The Usefulness of Mediastinal Cryobiopsy in the Diagnosis of Mediastinal Lymphadenopathy in HIV Patients.
Introduction: Mediastinal diseases in HIV patients show complex diagnostic challenges due to opportunistic infections and rare neoplasms. While Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a key technique, its effectiveness is limited as it only provides cytological samples. Endobronchial ultrasound-guided mediastinal cryobiopsy (CryoEBUS) emerges as a promising alternative, yielding larger and higher-quality samples. This study, the first in Mexico and the first worldwide in HIV patients, evaluates its diagnostic efficacy compared to EBUS-TBNA, highlighting its potential to improve disease management in immunocompromised populations.
Materials and methods: A prospective cross-sectional study has been conducted from April 2023 to October 2023 at a tertiary center for respiratory diseases in Mexico, evaluating the usefulness of the endobronchial ultrasound-guided mediastinal cryobiopsy (CryoEBUS) diagnostic in HIV-positive patients with mediastinal lymphadenopathy ≥1cm. Patients underwent CryoEBUS, with outcomes assessed via pathology and microbiology reports.
Results: Eleven patients were included (64% male, mean age 39.1 years). CryoEBUS yielded diagnostic results in 82% of cases compared to 72% for bronchoalveolar lavage (BAL) and 50% for EBUS alone. Combined CryoEBUS and BAL demonstrated the highest yield (91%).
Conclusion: In patients with HIV and mediastinal lymphadenopathy, mediastinal cryobiopsy has proven to be a useful, effective technique with a high diagnostic yield, especially for benign pathologies. It has also proven to be a safe technique and when combined with other lung sampling techniques, it improves the diagnostic yield of infectious diseases and rare neoplasms.
期刊介绍:
About Dove Medical Press Dove Medical Press Ltd is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC. We specialize in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine. Dove Medical Press was founded in 2003 with the objective of combining the highest editorial standards with the ''best of breed'' new publishing technologies. We have offices in Manchester and London in the United Kingdom, representatives in Princeton, New Jersey in the United States, and our editorial offices are in Auckland, New Zealand. Dr Scott Fraser is our Medical Director based in the UK. He has been in full time clinical practice for over 20 years as well as having an active research interest.